IRADIMED CORP

Iradimed reported Q1 2026 EPS of $0.49 (expectation $0.46) and revenue of $22 million (expectation $20.8 million), both above forecasts. Despite the strong numbers, the share price fell about 2.7% in premarket trading, possibly due to investor nervousness about other factors. The company sees continued growth in domestic sales and expects further revenue growth from the anticipated FDA approval and launch of the MRidium 3870. Risks remain supply‑chain issues, increased competition and macroeconomic pressure on hospital budgets. » Plus sur de.investing.com

Analysts show a strongly bullish consensus on IRADIMED, with three Buy ratings and a one-year median target near $118–$119 implying roughly 30–34% upside. Freedom Broker initiated coverage with a Buy and $116 target, citing the company's unique non-magnetic MRI-compatible IV infusion pumps and patient monitors, growth in ferromagnetic detection products, and attractive international expansion potential. The firm is described as profitable and dividend-yielding, supporting the positive investment case despite analyst notes that other sectors may offer different risk/return profiles. » Plus sur finance.yahoo.com

Iradimed reported GAAP EPS of $0.54 for Q4 2025 (expectation $0.48) and revenue of $22.7m (expectation $21.6m), with both metrics topping analysts' estimates. The company posted its 18th consecutive record quarter for revenue (+17% year‑on‑year) and full‑year revenue of $83.8m (+14%). The stock rose about 9.4% in premarket trading. Iradimed expects further growth from the launch of the MR‑Infusionspumpe 3870, is targeting a $100m run rate and plans expansion in Europe and Japan, but cites supply‑chain, regulatory and competitive risks. » Plus sur de.investing.com